Evidence mapPaperPMID 16423593Full record

Trial reportThe Journal of pediatrics2006

Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children.

Robert H Lustig, Michele L Mietus-Snyder, Peter Bacchetti, Ann A Lazar, Pedro A Velasquez-Mieyer, Michael L Christensen

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in The Journal of pediatrics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Observational
  8. [Clinical guidelines «Obesity in children»].Problemy endokrinologii · 2021
    Article
  9. Article
  10. Article
  11. Late endocrine effects of childhood cancer.Nature reviews. Endocrinology · 2016
    Review
  12. Treatment of obesity in children and adolescents.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2012
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Insulin resistance in children and adolescents.Reviews in endocrine & metabolic disorders · 2006
    Review
  18. Pediatric endocrine disorders of energy balance.Reviews in endocrine & metabolic disorders · 2005
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Robert H LustigDivision of Pediatric Endocrinology, Department of Pediatrics, University of California, San Francisco, USA. rlustig@peds.ucsf.edu
Michele L Mietus-Snyder
Peter Bacchetti
Ann A Lazar
Pedro A Velasquez-Mieyer
Michael L Christensen
University of California, San Francisco · USUniversity of Tennessee Health Science Center · US

Funding

ZIDOVUDINE &LAMIVUDINE &NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFM01RR001271 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 1985 to 2005
$21.3M
Type I Bovine Collagen Therapy of Systemic SclerodermaM01RR000211 · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 1985 to 2005
$8.1M
NCRR NIH HHS 5 M01 RR-01271NCRR NIH HHS M01 RR000211NCRR NIH HHS M01 RR000211-405806NCRR NIH HHS M01 RR001271NCRR NIH HHS M01-RR00211
6 · The paper itself

Abstract

objectiveTo assess the use of oral glucose tolerance testing (OGTT) to predict efficacy of insulin sensitization (metformin) or suppression (octreotide) because insulin resistance and insulin hypersecretion may impact pharmacotherapeutic efficacy in obese children. STUDY

designForty-three and 24 obese children, with and without central nervous system (CNS) insult, underwent OGTT. Insulin sensitivity was expressed as composite insulin sensitivity index (CISI), and secretion as corrected insulin response (CIRgp). Those without CNS insult received metformin (weight-based dosing) for 6 to 16 months. Those with CNS insult received octreotide SQ 15 microg/kg/d for 6 months. Body mass index (BMI) and z-score responses were modeled using CIRgp and CISI.

resultsMetformin: With CIRgp and CISI = 1, BMI z-score in white children declined by 0.23 over the first 4 months (P < .001), and by 0.14 over the next year (P = .33). Each 2-fold increase in CIRgp or CISI attenuated BMI z-score reduction, but with wide uncertainty (P = .24). Black children exhibited little response. Octreotide: With CIRgp and CISI = 1, BMI z-score decreased by 0.23 in the first 4 months (P = .052). Efficacy was dependent on an interaction between CIRgp and CISI (P = .051).

conclusionsEfficacy of metformin was predicted by pretreatment insulin resistance. Efficacy of octreotide was predicted by insulin hypersecretion and sensitivity.

Indexed as

Body Mass IndexAdolescentBlack PeopleBlood GlucoseCentral Nervous System DiseasesChildChild, PreschoolFemaleHumansHypoglycemic AgentsInfantInsulinInsulin ResistanceLinear ModelsMaleMetforminBlood GlucoseHypoglycemic AgentsInsulinMetforminOctreotide

Identifiers

PMID16423593
PMCPMC1550350
OpenAlexW2107123059

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.